Defining Pathways for Development of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report-Reference-Cited by-同舟云学术

Defining Pathways for Development of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report

Published:2015-09-15 Issue:10 Volume:38 Page:1975-1985
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Wherrett Diane K.¹,Chiang Jane L.²,Delamater Alan M.³,DiMeglio Linda A.⁴,Gitelman Stephen E.⁵,Gottlieb Peter A.⁶,Herold Kevan C.⁷,Lovell Daniel J.⁸,Orchard Trevor J.⁹,Ryan Christopher M.¹⁰,Schatz Desmond A.¹¹,Wendler David S.¹²,Greenbaum Carla J.¹³,

Affiliation:

1. Department of Pediatrics, University of Toronto, Toronto, Canada

2. American Diabetes Association, Alexandria, VA

3. Department of Pediatrics, University of Miami, Miami, FL

4. Department of Pediatrics, Indiana University, Indianapolis, IN

5. Department of Pediatrics, University of California, San Francisco, San Francisco, CA

6. Departments of Medicine and Pediatrics, University of Colorado, Denver, CO

7. Department of Immunobiology, Yale University, New Haven, CT

8. Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

9. Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA

10. Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA

11. Department of Pediatrics, University of Florida, Gainesville, FL

12. Department of Bioethics, National Institutes of Health, Bethesda, MD

13. Diabetes Research Program, Benaroya Research Institute, Seattle, WA

Abstract

Emerging data suggest that type 1 diabetes is a more aggressive disease in children than in adults, with important differences in pathophysiology and clinical course. Therefore, the efficacy of disease-modifying therapies may be different in the two populations. Understanding the developmental and regulatory pathways for type 1 diabetes–modifying therapies in children will enable industry, academia, funders, advocacy groups, and regulators to translate new science to clinical care. This consensus report characterizes the fundamental differences in type 1 diabetes between children and adults and proposes a thoughtful approach to better understand the development and regulatory pathways for type 1 diabetes therapies.

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/38/10/1975/622917/dc151429.pdf

Reference99 articles.

1. Trends in incidence of type 1 diabetes among non-Hispanic white youth in the U.S., 2002-2009;Lawrence;Diabetes,2014

2. The changing epidemiology of type 1 diabetes: why is it going through the roof?;Vehik;Diabetes Metab Res Rev,2011

3. Incidence of type 1 diabetes in Sweden among individuals aged 0-34 years, 1983-2007: an analysis of time trends;Dahlquist;Diabetes Care,2011

4. The SEARCH for Diabetes in Youth study: rationale, findings, and future directions;Hamman;Diabetes Care,2014

5. Prevalence of diabetes in U.S. youth in 2009: the SEARCH for Diabetes in Youth study;Pettitt;Diabetes Care,2014

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapies for Type 1 Diabetes;Textbook of Diabetes;2024-01-12

2. Predicting Immunological Risk for Stage 1 and Stage 2 Diabetes Using a 1-Week CGM Home Test, Nocturnal Glucose Increments, and Standardized Liquid Mixed Meal Breakfasts, with Classification Enhanced by Machine Learning;Diabetes Technology & Therapeutics;2023-09-01

3. Evaluating the effect of prebiotics on the gut microbiome profile and β cell function in youth with newly diagnosed type 1 diabetes: protocol of a pilot randomized controlled trial;Pilot and Feasibility Studies;2023-08-25

4. Novel mechanism-based treatments for pediatric anxiety and depressive disorders;Neuropsychopharmacology;2023-08-22

5. Age Ain’t Nothing But a Number . . . or Is It?;Diabetes Care;2023-05-23